Rubraca
Active Ingredient(s): RucaparibFDA Approved: * December 19, 2016
Pharm Company: * Clovis Oncology, Inc.
Category: Cancer
Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is approved in the United States and in Europe as third line treatment in BRCA-mutated ovarian cancer.[3][4][5] It can be taken orally in tablet form.[2][6] The most common side effects include ti... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
